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ABSTRACT
Lung diseases are devastating conditions and ranked as one of the top five causes of mortality world-
wide according to the World Health Organization. Stem cell therapy is a promising strategy for lung
regeneration. Previous animal and clinical studies have focusedon the use ofmesenchymal stem cells
(fromotherpartsof thebody) for lung regenerative therapies.Wereporta rapidand robustmethod to
generate therapeutic resident lung progenitors from adult lung tissues. Outgrowth cells from healthy
lung tissueexplantsare self-aggregated into three-dimensional lungspheroids ina suspensionculture.
Without antigenic sorting, the lung spheroids recapitulate the stem cell niche and contain a natural
mixture of lung stem cells and supporting cells. In vitro, lung spheroid cells can be expanded to a large
quantity and can formalveoli-like structures andacquiremature lung epithelial phenotypes. In severe
combined immunodeficiencymicewith bleomycin-induced pulmonary fibrosis, intravenous injection
of human lung spheroid cells inhibited apoptosis, fibrosis, and infiltrationbut promotedangiogenesis.
In a syngeneic rat model of pulmonary fibrosis, lung spheroid cells outperformed adipose-derived
mesenchymal stem cells in reducing fibrotic thickening and infiltration. Previously, lung spheroid cells
(the spheroid model) had only been used to study lung cancer cells. Our data suggest that lung sphe-
roids and lung spheroid cells from healthy lung tissues are excellent sources of regenerative lung cells
for therapeutic lung regeneration. STEM CELLS TRANSLATIONAL MEDICINE 2015;4:1265–1274
SIGNIFICANCE
Theresults fromthepresent studywill leadtofuturehumanclinical trialsusing lungstemcell therapies to
treat various incurable lungdiseases, includingpulmonary fibrosis. Thedata presentedhere alsoprovide
fundamental knowledge regarding how injected stem cells mediate lung repair in pulmonary fibrosis.
INTRODUCTION
Lung diseases, such as chronic obstructive pul-
monary disease (COPD) and idiopathic pulmonary
fibrosis (IPF), are devastating conditions and,
according to the World Health Organization, in the
top five causes of mortality worldwide [1]. Stem
cell therapy is a promising approach for lung re-
generative medicine [2]. Pluripotent cells, such as
embryonic stem cells or induced pluripotent stem
cells, hold great differentiation and proliferation
potential. However, clinical translation has been
hampered by the potential teratogenic risk in hu-
man trials [3–5]. Current preclinical and clinical
efforts are focusing on the infusions of adult stem
cells isolated from human bone marrow, adipose
tissue, placental tissue, or cord blood (referred to
as mesenchymal stem cells or stromal cells) to treat
patients with COPD, bronchopulmonary dysplasia,
bronchiolitis obliterans, asthma, or acute lung
injury [6–9]. However, a variety of resident lung
stem cell types have been identified [10–15]. Com-
pared with mesenchymal stem cells, the isolation
and expansion of these resident lung stem cells
for clinical usage remains a challenge. Antigenic
sorting and purification are normally required. Fur-
thermore, it is yet to be determined which surface
marker ormarkerswill identify thebest cell sources
for lung regenerative therapies.
Wesought todeveloparapid, reproducible,and
scalable method to generate clinically applicable
amounts of resident lung progenitors. Multicellular
spheroidsrepresentathree-dimensionalcell culture
method frequently used in cancer biology [16, 17].
The spheroid method has also been used to gener-
ateneural stemcells [18] andcardiac stemcells [19].
It has also been reported that the spheroid micro-
environment mimics the in vivo stem cell niche
and is able to reprogram somatic cells into neural
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TISSUE-SPECIFIC PROGENITOR AND STEM CELLS
lung spheroids could be generated from healthy lung tissues and
might contain lung progenitor cells suitable for therapeutic applica-
tions. In the present study, outgrowth cells from adult human lung
tissues were self-aggregated into three-dimensional multicellular
lung spheroids. When replated onto fibronectin-coated surfaces,
the lung spheroids dissociated into single cells, which we termed
“lung spheroid cells” (LSCs). Lung spheroids and LSCs represent nat-
ural mixtures of both lung progenitors and supporting stromal cells.
Intravenous infusionofhumanLSCsamelioratedbleomycin-induced
pulmonary fibrosis (PF) in immunodeficiencymice. In a ratmodel of
pulmonary fibrosis, a head-to-head comparison revealed the thera-
peutic superiority of LSCs over adipose-derived mesenchymal stem
cells with the same genetic background.
MATERIALS AND METHODS
Generation of Lung Spheroids and Lung Spheroid Cells
Healthy human lung tissues were acquired from the Cystic Fibrosis
and Pulmonary Diseases Research and Treatment Center at the
University of North Carolina-Chapel Hill. Donor comorbidity is
shown in supplemental online Table 1. An approximately 6 mm3
6 mm sample of distal lung tissue was separated and washed
with phosphate-buffered saline (PBS) (Life Technologies, Carlsbad,
CA,http://www.lifetechnologies.com). The tissuesamplewas then
cut into smaller biopsy-size pieces and washed three times with
PBS, followed by enzymatic digestion at 37°C in 5 mg/ml colla-
genase i.v. solution (Sigma-Aldrich, St. Louis, MO, http://www.
sigmaaldrich.com) for 5 minutes. Iscove’s modified Dulbecco’s me-
dium (IMDM; Life Technologies) containing 20% fetal bovine serum
(FBS; Corning Life Sciences, Acton, MA, http://www.corning.com/
lifesciences) was then added to the sample to inactivate the col-
lagenase. Subsequently, the tissue samples were minced into
smaller tissue explants (∼0.53 0.5 mm) before plating. Approx-
imately 50 pieces of tissue explants were then placed onto a
fibronectin-coated plate with approximately 1.5 cm between each
explant and covered with 2ml of IMDMwith 20% FBS overnight to
aid their attachment onto the plate. The cultures were maintained
in IMDMwith 20% FBS, and a medium change was performed every
other day. In approximately 1 week, cells started to outgrow from
the tissue explants. Once these outgrowth cells were approximately
70%–80% confluent, they were harvested by 5–10 minutes of in-
cubation with TryPLE Select (Life Technologies). The cells were
then seeded into an ultra-low-attachment flask (Corning Life Sci-
ences) at a density of 100,000 cells per cm2 and cultured in IMDM
with10%FBS for spheroid formation. Phase-bright lung spheroids
started to form in 3–7 days. Lung spheroids were then collected
from the suspension culture and replated onto a fibronectin-
coated surface to generate adherent LSCs. LSCs were cultured
in IMDM containing 20% FBS, 50 mg/ml gentamicin, 2 mmol/
l L-glutamine (Life Technologies), and 0.1 mmol/l 2-mercaptoe-
thanol (Life Technologies). A cohort of LSCs were cultured in FBS-
free medium containing 25 ng/ml epidermal growth factor (EGF;
Shenandoah Biotechnology, Warwick, PA, http://www.shenandoah-
bt.com) to test the effects of EGF on cell growth. The cells were
passaged every 3–5days.Weused passage 2–3 LSCs for all in vitro
and in vivo testing. Human pulmonary alveolar epithelial cells
(HPAEpiC; ScienCell Research Laboratories, Carlsbad, CA, http://
www.sciencellonline.com) and normal human dermal fibroblast
cells (NHDFs; American Type Culture Collection, Manassas, VA,
http://www.atcc.org) were cultured in the same medium as the
control cells to human LSCs. Rat LSCs were generated from
6-week-old syngeneic Wistar-Kyoto rats using a similar protocol
as for human LSCs. Rat adipose-derived mesenchymal stem cells
(AD-MSCs) were derived from the same strain of rats as previously
described [22]. Mouse PF-LSCs were generated from 6-week-old
CD1 mice (Charles River Laboratories, Wilmington, MA, http://
www.criver.com) 14 days after bleomycin instillation. Lung biopsy
tissues from IPF patients were obtained from the IPF Clinic of
University of North Carolina-Chapel Hill.
Flow Cytometry Analysis
To characterize the antigenic phenotypes of LSCs, flow cytometry
was performedusing a FACSCalibur or an LSR II flow cytometer (BD
Biosciences, San Diego, CA, http://www.bdbiosciences.com) and
analyzed using FlowJo software (TreeStar, Ashland, OR, http://
www.flowjo.com). The cells were incubatedwith antibodies against
CD31, CD34, CD45, CD90, CD105, Clara cell secretory protein (CCSP),
pro-surfactant protein c (Pro-SPC), and aquaporin 5 for 60 minutes.
Isotype-identical antibodies served as the negative control. Human
bonemarrow-derivedmesenchymal stem cells (BM-MSCs) were ob-
tained fromLonza (Walkersville,MD,http://www.lonza.com) as con-
trol cells for flow cytometry, and the BM-MSCs were cultured in the
same LSC medium. To reveal the change in cell phenotype from
spheroids to adherent cells, the lung spheroidswere dissociated into
single cells by 10–15 minutes of incubation with TryPEL Select (Life
Technologies), and the dissociated cells were subjected to flow
cytometry analysis.
Immunocytochemistry on Lung Spheroids and LSCs
LSCs were plated onto fibronectin-coated chamber slides (BD Bio-
sciences) and subsequently fixedwith 4% paraformaldehyde (PFA)
before immunocytochemistry. Lung spheroids were mounted in
Tissue-Tek O.C.T. compound (Sakura Finetek, Tokyo, Japan, http://
www.sakura-finetek.com) and cryosectioned (5 mm). LSCs or lung
spheroid sections were stained with the antibodies against CD31,
CD34, CD45, CD90, CD105, CCSP, Pro-SPC, KRT5, p63, and aquaporin
5 and detected by fluorescein isothiocyanate (FITC)- or Texas Red-
conjugated secondary antibodies (Abcam, Cambridge, MA, http://
www.abcam.com/). Images were taken with an epifluorescent mi-
croscope (Olympus IX81; Olympus, Center Valley, PA, http://
www.olympusamerica.com).
In Vitro Differentiation and Paracrine Assays
LSCs were transducedwith viral particles of enhanced green fluo-
rescent protein (EGFP; Vector Biolabs, Malvern, PA, http://www.
vectorbiolabs.com). The cells were plated onto Matrigel (BD Bio-
sciences) in serum-freemedia for observation of the formation of
alveoli-like structures in vitro. Furthermore, LSCs on Matrigel
were fixed with 4% PFA, followed by immunostaining on EGFP
and aquaporin 5. Nuclei were counterstained with 49,6-diamidino-
2-phenylindole. To reveal the effects of LSC-secreted factors on
lung epithelial cell survival, HPAEpiCs were cultured in control
media (plain IMDM) or LSC-conditioned media. After 3 days, live
and dead HPAEpiCs were stained with Calcein-AM and ethidium
homodimer-1, respectively (Live/Dead Assay Kit; Life Technologies).
The proangiogenic effects of LSC-conditioned media were studied
by endothelial cell tube formation assay. Human umbilical vein
endothelial cells (HUVECs;AmericanTypeCultureCollection )were
seeded onto growth factor-reduced Matrigel in 96-well plates
at a density of 2 3 104 cells per well. Next, 100 ml of plain
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IMDM or conditioned media from human LSCs were added to
the wells. After 4 hours, the wells were imaged with a Nikon
TE-200 white light microscope (Nikon, Tokyo, Japan, http://
www.nikon.com). The average tube length was then measured
with NIH ImageJ software. To compare the secretion of human LSCs
andNHDF cells, conditionedmedia from the twowere collected and
assayed with an antibody array (RayBiotech, Norcross, GA, http://
www.raybiotech.com).
Animal Procedures
All animal work was compliant with the Institutional Animal Care
and Use Committee at North Carolina State University. We ran-
domized 6–8-week-old female severe combined immunodefi-
ciency (SCID) mice (Charles River Laboratories) into the following
three treatment groups (n = 6–7mice for each group): (a) sham con-
trol: mice receiving 50 ml of PBS instilled intratracheally into the
lungs; (b) Bleo + saline: mice receiving 0.7 U/kg body weight bleo-
mycin in 50 ml of PBS (EMD Millipore, Bilerica, MA, http://www.
emdmillipore.com/) instilled intratracheally into the lungs, followed
by tail vein injection of 200 ml of PBS 24 hours later; and (c) Bleo +
LSC: mice receiving 0.7 U/kg body weight bleomycin in 50 ml of
PBS instilled intratracheally into the lungs, followed by tail vein
injection of 13 106 human LSCs in 200 ml of PBS 24 hours later. A
subset of animals in theBleo + LSC group received LSCs labeledwith
green fluorescent cell tracker DiO (Life Technologies) or transduced
with viral particles of EGFP (Vector Biolabs), facilitating histological
detection of engrafted LSCs in the mouse lungs. At day 14, all mice
were sacrificed, and their lungswereharvested forhistological anal-
ysis, including hematoxylin and eosin (H&E) staining for alveolar
thickening and infiltration, Masson’s trichrome staining for fibrosis,
terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL)
assay (Sigma-Aldrich) for cell apoptosis, and immunohistochemistry
staining on LSCs. To perform a head-to-head comparison of LSCs and
another stem cell type in lung regeneration, 53 106 syngeneic rat
LSCs or AD-MSCs were injected into 6-week-old femaleWistar-Kyoto
rats (Charles River Laboratories) with bleomycin-induced pulmonary
fibrosis. The animals were euthanized 14 days later. The same
H&E staining was performed to measure the degree of lung injury.
Histology
All the animals were sacrificed 14 days after treatment. The
mouse lungswere harvested and frozen in Tissue-TekO.C.T. com-
pound (Sakura Finetek). Cryosections (5 mm thick) were pre-
pared. For H&E staining, lung cryosections were stained for
2 minutes in hematoxylin and 30 seconds in eosin. Masson’s
trichrome staining was performed as per the manufacturer’s
instructions [HT15 Trichrome Staining (Masson) Kit; Sigma-
Aldrich]. For immunofluorescence staining, lung cryosections
were fixed with 4% PFA, blocked and permeabilized with Protein
Block Solution (Dako, Carpinteria, CA, http://www.dako.com)
containing 1% saponin (Sigma-Aldrich), and then stained with
the following antibodies: rabbit anti-vonWillebrand factor (Abcam),
rabbit anti-Aquaporin5 (Abcam), and chickenanti-GFP (Abcam). FITC
or Texas-Red secondary antibodies were also obtained from Abcam.
Images were taken using a Zeiss LSM 710 laser scanning confocal
microscopy system (Carl Zeiss, Jena, Germany, http://www.zeiss.
com). Apoptotic cells were detected by TUNEL assay using the In
Situ Cell Death Detection Kit (Roche Diagnostics, Mannheim,
Germany, http://www.roche-applied-science.com) according
to the manufacturer’s instructions.
Polymerase Chain Reaction Array
Using the RT2 Profiler PCR Array System (Qiagen, Hilden, Ger-
many, http://www.qiagen.com), we compared the expression
of stem cell-related genes in human LSCs and HPAEpiCs. In brief,
total RNAwasextracted fromexplanted lungs andcDNAprepared
from the total RNAmixture of three independent lungs using the
RT2 First Strand Kit (Qiagen). An experimental cocktail was pre-
pared by adding cDNA to RT2 qPCR Master Mix (Qiagen) within
the 96-well polymerase chain reaction (PCR) array. Quantitative
real-time PCRwas performedwith a Roche Light Cycler Real Time
PCR System (Roche Diagnostics). A similar fibrosis-related gene
PCR array was used to compare the expression of key genes in-
volved in dysregulated tissue remodeling during the repair and
fibrosis in the Bleo + saline and Bleo + LSC lungs.
Statistical Analysis
The results are presented as the mean 6 SD, unless specified
otherwise. Comparisons between any two groups were per-
formed using 2-tailed unpaired Student’s t tests. Comparisons
among more than two groups were performed using one-way
analysis of variance followed by post hoc Bonferroni correction.
Differences were considered statistically significant at p , .05.
RESULTS
Generation of Lung Spheroids and LSCs
Using a three-dimensional suspension culture (Fig. 1A), we de-
rived lung spheroids and LSCs from healthy adult human lung tis-
sues. Both phase-bright and stromal-like cells started to outgrow
from the lung tissue explants in 1 week after plating onto
fibronectin-coated surfaces. Those outgrowth cells become con-
fluent in∼2–3 weeks (Fig. 1B-I). When seeded onto an ultra-low-
attachment surface (Corning Life Sciences) (to discourage cell
attachment), the outgrowth cells spontaneously aggregated into
three-dimensional lung spheroids (Fig. 1B-II).When replatedonto
a fibronectin-coated surface, the lung spheroids dissociated into
single cells that we termed “lung spheroid cells” (Fig. 1B-III). One
biopsy-size lung tissue sample can generate 10–20 million pas-
sage 0 LSCs. When maintained and passaged in IMDM with
20% FBS (Fig. 1B-IV), LSCs can further undergo 5–15 doublings
within 15–50 days (Fig. 1C). Such cell yield and growth potential
should suffice the requirement for clinical cell manufacturing.
Cell Phenotypes in Lung Spheroids and LSCs
Immunocytochemistry revealed an organized structure in the
lung spheroids (Fig. 1D). Clusters of lung progenitor cells (e.g.,
Pro-SPC- and/or CCSP-positive cells, p63-positive cells, and
KRT5-positive cells) reside in the spheroid core surrounded by
CD105-positive and CD90-positive supporting (stromal-like) cells.
These architectural features of lung spheroids resemble previ-
ously reported stem cell niches found in cardiac stem cell-
formed spheroids [23]. Lung spheroids did not contain cells
expressing hematopoietic markers such as CD45, CD31, and
CD34 and had a low expression of the mature alveoli epithelial
marker aquaporin 5. As the single-cell derivatives of lung sphe-
roids, LSCs displayed a similar phenotypic profile. Flow cytometry
analysis (Fig. 2A, 2C) revealed that LSCs were positive for CD105,
CD90, Pro-SPC, and CCSP. Double staining confirmed that a sub-
population of LSCs was positive for both Pro-SPC and CCSP
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(Fig. 2D). LSCs are negative for hematopoietic cell markers CD45,
CD31, CD34, and express a negligible percentage of the mature
lung epithelial marker aquaporin 5. These compound data sug-
gest that LSCs represent a selective mixture of lung progenitor
cells and supporting cells. The phenotype of LSCs was distinct
from that of BM-MSCs, because the latter did not express Pro-
SPC or CCSP (supplemental online Fig. 1). To reveal the changes
of cell phenotype from spheroids to adherent cells, we dissociated
lung spheroids into single cells and then performed flow cytom-
etry analysis. The results indicated a similar phenotype, except for
slightly higher Pro-SPC expression at the spheroid stage
(supplemental online Fig. 2). Immunocytochemistry on LSCs con-
firmed the flow cytometry results (Fig. 2B). To enable histolog-
ical detection, a cohort of LSCs were transduced with EGFP
viral particles. We confirmed that EGFP transduction did not
affect the phenotype of LSCs (supplemental online Fig. 3).
Figure 1. Generation of lung spheroids and lung spheroid cells. (A): Schematic showing the protocol to grow lung spheroids and lung spheroid
cells. (B-I): Edge of lung tissue explants with outgrowth cells becoming confluent and ready to harvest. (B-II): Lung spheroids formed from out-
growth cells in suspension culture. (B-III): Plated lung spheroids onto fibronectin-coated surfaces to generate lung spheroid cells. (B-IV): Ex-
pansion of LSCs in suspension cultures. (C): Cumulative doubling for LSCs from three different donors. (D): Immunocytochemistry on lung
spheroids. Scale bars = 50 mm. Abbreviations: LSCs, lung spheroid cells; PF, pulmonary fibrosis; SCID, severe combined immunodeficiency.
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Using a stemness-related gene PCR array, we compared the gene
expression of human LSCs and HPAEpiCs (Fig. 2E). Multiple genes
were upregulated in LSCs compared with HPAEpiCs, such as bone
morphogenetic protein2, stromal cell-derived factor 1 (also known
as C-X-C motif chemokine 12), and fibroblast growth factor 2.
In Vitro Differentiation and Paracrine Assays
When cultured on Matrigel (BD Biosciences), LSCs self-assembled
into alveoli-like structures (Fig. 3A). Immunostaining revealed that
LSCs expressed aquaporin 5 (Fig. 3B, overlay of red/greenwith open
arrowheads,) and acquired mature lung epithelial cell morphology.
Nondifferentiated LSCs (Fig. 3B, green with solid arrowheads)
remained positive for Pro-SPC (supplemental online Fig. 4, white ar-
row). Conditioned media from LSCs promoted survival or prolifera-
tion of human lung epithelial cells (Fig. 3C) and tube formation of
humanendothelial cellsonMatrigel (LSC-conditionedmedia vs. con-
trolmedia, 237.86 32.7mmvs. 108.76 81.1mm; p, .05; Fig. 3D),
suggesting a prosurvival and proangiogenic role of LSC-secreted fac-
tors. A cytokine array (Fig. 3E) revealed that compared with control
cells (NHDFs), human LSCs secreted higher concentrations of proan-
giogenic factors such as insulin-like growth factor binding protein
2, hepatocyte growth factor, and brain-derived neurotrophic factor.
Regenerative Potential of LSCs in Mice With
Pulmonary Fibrosis
Theanimal studydesign isoutlined inFigure 4A.Pulmonary fibrosis
was induced in SCIDmiceby intratracheal instillationof bleomycin;
24 hours later, the animals received an intravenous infusion of 13
106human LSCsor saline control. The animalswere followedup for
another 14 days and then sacrificed for endpoint analysis. The mac-
roscopic view of the explanted lungs revealed significant tissue
damage (dense dark spots) in the Bleo + saline lungs (Fig. 4B). In
contrast, the LSC-treated lungs (Bleo + LSC group) were similar
to the lungs in the shamgroup. H&E staining (Fig. 4C) revealed that
LSC treatment significantly reduced fibrous thickening (byAshcroft
score; Bleo + saline vs. Bleo + LSC, 5.76 1.0 vs. 4.36 0.7; Fig. 4E)
and tissue infiltration (Bleo + saline vs. Bleo + LSC, 11.6 6 5.7 vs.
4.3 6 4.8; Fig. 4F). Masson’s trichrome staining confirmed the
reduction of fibrosis with LSC treatment (Fig. 4D, blue).
Mechanisms of LSC-Mediated Lung Protection
and Regeneration
LSC engraftment reduced tissue apoptosis in the bleomycin-
treated lungs. LSC engraftment (DiO-labeled; Fig. 5A, green) de-
creased the numbers of TUNEL-positive apoptotic cells (Fig. 5A,
red nuclei) in the bleomycin-treated lungs (area without LSC vs.
area with LSC, 1.9%6 0.5% vs. 0.7%6 0.2% of total nuclei). Such
protection was seen in epithelial, stromal, and endothelial cell
types in the lungs (supplemental online Fig. 5). In contrast, LSC
treatment increased angiogenesis in the bleomycin-treated
lungs:more vonWillebrand factor-positive vasculatures were de-
tected in the LSC-treated lungs (Bleo + saline vs. Bleo + LSC, 6.06
2.3 vs. 11.8 6 3.3 per high power field; Fig. 5B). Moreover,
a greater number of blood vessels were formed around LSCs than
in other areas without the presence of LSCs (supplemental online
Fig. 6). These results were consistent with the prosurvival and
proangiogenic effects of LSCs observed in vitro (Fig. 3). Although
some injected human LSCs acquired mature lung epithelial cell
phenotypes (e.g., EGFP-positive LSCs coexpressed differentiation
of the lung epithelial cell marker aquaporin 5 [Fig. 5C, white
arrows; supplemental online Fig. 7, inset b]), some LSCs remained
positive for Pro-SPC (supplemental online Fig. 7, inset b). To reveal
Figure 2. Lung spheroid cells contain lung progenitor cells. (A): Representative flow cytometry plots of LSCs for expression of CD31, CD34,
CD45, CD90, CD105, CCSP, Pro-SPC, and aquaporin 5. Black lines indicate isotype controls; red lines, antibodies. (B): Immunocytochemistry
staining of LSCs for the same markers. (C): Pooled data for the expression of the same markers (n = 3 lung donors). (D): Double staining of
Pro-SPC and CSSP in LSCs. (E): Polymerase chain reaction array showing relative expression of stem cell genes in human LSCs and alveolar
epithelial cells. Scale bars =10mm.Abbreviations: AEC, alveolar epithelial cell; AQ5, aquaporin 5;BMP2, bonemorphogenetic protein 2;CXCL12,
C-X-C motif chemokine 12; FGF2, fibroblast growth factor 2; Q, quartile.
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Figure 3. In vitro differentiation and paracrine assays of lung spheroid cells. (A): LSCs grown on Matrigel and displaying alveoli-like structures
(inset). (B): LSCs grownonMatrigel expressed aquaporin 5 (red). (C):Human lung epithelial cells cultured in controlmedia and LSC-CMand stained
for live(green)/dead(red)assay. (D):HUVECtubeformationassayonMatrigel surface incontrolorconditionedmedia fromLSCs.Dataarepresented
asmean6SD.All experimentswererun in triplicate, unlessnotedotherwise. Scalebars=50mm.p,p, .05comparedwith the controlmedia group.
(E): Representative antibody array images showing the proteins presenting in the CM from LSCs and NHDF cells. Abbreviations: AQ5, aquaporin 5;
BDNF, brain-derivedneurotrophic factor;CM, conditionedmedia;DAPI, 49,6-diamidino-2-phenylindole; EGFP,enhancedgreen fluorescentprotein;
GRO, growth-regulated protein; HGF, hepatocyte growth factor; HUVEC, human umbilical vein endothelial cell; IGFBP2, insulin-like growth factor
binding protein 2; IL, interleukin; LSCs, lung spheroid cells; POS, positive; NHDF, normal human dermal fibroblast cell.
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the overall impact of LSC treatment on pulmonary fibrosis, we
extractedRNAfromthe lungs fromtheBleo+ LSCandBleo+ saline
groups. Quantitative PCR array revealed that LSC treatment at-
tenuated the expression of fibrotic genes in the bleomycin-
treated lungs (Fig. 5D; supplemental online Table 2).
Therapeutic Superiority of LSCs Over AD-MSCs
Becausemost current clinical trials are usingMSCs to treat IPF and
COPD, we sought to compare the therapeutic potencies of LSCs and
AD-MSCs. To ruleoutdonor variability,wederived rat LSCsandAD-
MSCs from the syngeneic Wistar-Kyoto (WKY) rat strains, because
these rats share the same genetic background. Rat LSCs share a
similar antigenic phenotype with their human counterparts, with
consistent expression of CD105, CD90, Pro-SPC, and CCSP
(supplemental online Fig. 8). At 24 hours after bleomycin instilla-
tion, WKY rats were randomized to receive saline, rat LSCs, or
rat AD-MSCs (Fig. 6A). Consistentwith previous reports, H&E stain-
ing indicated that AD-MSC therapy reduced infiltrates by 14 days
after cell therapy (Fig. 6B–6D, black bars) comparedwith the saline
control (Fig. 6B–6D, white bars). A trend was also seen toward the
reduction of fibrotic thickening (by Ashcroft score). However, the
highest therapeutic effects were observed in the rats that received
LSCs; they expressed the smallest degree of fibrotic thickening and
tissue infiltration (Fig. 6B–6D, red bars). These data suggest that
LSCs are superior to AD-MSCs in treating rats with PF.
DISCUSSION
The past decadewitnessed a burst of studies on identifying endog-
enous lung stem cells [24]. Many cell types in the lung, including
basal cells, club cells, and alveolar type II cells, have been proposed
as lung stem/progenitor cells. However, mesenchymal cells (from
bonemarrow,adiposetissues,umbilical cord)arestill themajorplay-
ers inon-goingcell-basedclinical trials for treating lungdiseases,due,
at least in part, to the ease of isolating and propagating these cells.
Multicellular spheroids have been used as a method to gen-
erate neural and cardiac stem cells. A recent report indicated
infusion of cardiosphere-derived cells in patients with a mild-to-
moderate heart attack reduced scar and increased viable tissue
[25]. To date, lung spheroids have only been recognized as
a method to grow lung cancer cells [26]. In the present study,
we have shown that lung spheroids from healthy lungs represent
a robust method to generate therapeutic lung progenitor cells.
The cell yield and growth potential of LSCs are suitable for both
autologous and allogeneic applications (Fig. 1). No antigenic sort-
ing is required. LSCs represent a natural mixture of both lung pro-
genitor cells and supporting cells (Fig. 2). The origin of LSCs is yet
to be determined. The expression of CD105, CD90, Pro-SPC, and
CCSP identified human LSCs, suggesting that they might contain
lung mesenchymal stem/stromal cells (CD105+/CD90+), alveolar
progenitor cells (Pro-SPC+), and airway progenitor cells (CSSP+).
LSCs are distinct from MSCs: human MSCs express CD105 and
CD90 but not Pro-SPC or CCSP (supplemental online Fig. 1). A sub-
fraction of LSCswas dual positive for Pro-SPCandCSSP, suggesting
they might represent a population of bronchioalveolar stem cells.
This naturalmixtureof lungprogenitor cells couldbea resultof the
ex vivo cell culture process. The three-dimensional spheroid cul-
turemight enrich the stem cell populations. Alternatively, mature
lung epithelial cells can revert into progenitor cells, a process re-
sembling the dedifferentiation of lung cells into stem cells in vivo
Figure 4. Therapeutic benefits of human LSCs in mice with bleomycin-induced pulmonary fibrosis. (A): Schematic showing the design of the
mouse studies. (B):Macroscopic viewsofexplanted lungs14days after LSCor saline treatment.H&Estaining (C)andMasson’s trichromestaining
(D) were performed on the lungs. (E): Quantitation of fibrous thickening by Ashcroft score from the H&E staining images (n = 6–7 animals per
group). (F):Quantitation of tissue infiltrates from the H&E staining images (n = 6–7 animals per group). Data are presented asmean6 SD. Scale
bars =100mm.p,p, .05 comparedwith the shamgroup;#,p, .05 comparedwith theBleo+ salinegroup. Abbreviations: Bleo, bleomycin; H&E,
hematoxylin and eosin; LSCs, lung spheroid cells.
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[27]. LSCs were able to form alveoli-like structures and acquired
mature lung epithelial phenotypes/morphologies in vitro, sug-
gesting their differentiation potential (Fig. 3A, 3B). The condi-
tioned media from LSCs promoted lung epithelial cell survival
(Fig. 3C) and endothelial cell tube formation (Fig. 3D). Cytokine ar-
ray data suggested that LSCs might promote lung regeneration
through the secretion of antiapoptotic and proangiogenic factors
and cytokines (Fig. 3E).
To test the regenerative potential of LSCs in vivo, we created
a pulmonary fibrosis model in mice via intratracheal instillation of
bleomycin. The use of immunodeficiency (SCID) mice makes it pos-
sible to test human LSCswithout fear of rejection. No complications
Figure 5. Mechanisms underlying the therapeutic effects of LSCs in pulmonary fibrosis. (A): Representative confocal images showing the num-
bers of apoptotic cells (red nuclei) in area with and without LSC engraftment (green) (n = 4 animals per group). (B): Representative confocal
images showing vWF-positive vasculature (red) in the lungs treated with saline or LSCs (n = 4 animals per group). (C): Representative confocal
images showing engrafted EGFP-positive LSCs coexpress mature lung epithelial cell marker aquaporin 5. (D): Quantitative polymerase chain
reaction array showing the expression of fibrosis-related genes in lungs treated with saline or LSCs (using a cutoff criterion of a fold change
.1.5). (E): Proposed mechanisms for LSC-mediated lung repair in pulmonary fibrosis. Data are presented as mean 6 SD. Scale bars = 20 mm.
p, p , .05 using unpaired Student’s t tests. Abbreviations: AQ5, aquaporin 5; Bleo, bleomycin; DAPI, 49,6-diamidino-2-phenylindole; EGFP,
enhanced green fluorescent protein; HPF, high power field; LSCs, lung spheroid cells; POS, positive; TUNEL, terminal deoxynucleotidyl trans-
ferase dUTP nick-end labeling; vWF, von Willebrand factor; w/, with; w/o, without.
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wereobserved in themice that received the LSC infusion.No tumors
or ectopic tissues were observed in any of the animals treated with
LSCs. Treatmentwith LSCs inhibited fibrosis (Fig. 4E), infiltration (Fig.
4F), and cell apoptosis (Fig. 5A) but promoted angiogenesis (Fig. 5B).
LSCs engrafted and acquired mature lung phenotypes in the recipi-
ent lungs (Fig. 5C), although such small engraftment and differenti-
ation incidents seem insufficient to explain the overall benefits.
Mounting lines of evidence suggest that injected stemcells regener-
ate damaged tissues through indirect paracrine mechanisms [28].
We speculate LSCs secrete beneficial factors that modulate the en-
vironment and recruit endogenous repair mechanisms (Fig. 5E).
BecauseMSCsare themostpopular cells in clinical trials for lung
diseases,weperformedahead-to-head comparison of rat LSCs and
AD-MSCs in the same rat model of PF (Fig. 6). LSCs outperformed
AD-MSCs in reducing fibrotic thickening and tissue infiltration in
PF lungs.Theunderlyingmechanismsneedtobefurtherelucidated.
Because thesewerederived fromadult lungs insteadof adipose tis-
sue, we speculate that LSCs are predesignated to differentiate into
lung cells and promote endogenous lung regeneration.
Our study also had several limitations. First, wedid not isolate
the MSC population from the LSC mixture and then perform
ahead-to-head comparisonof the two invitro and invivo. Second,
the injection of stem cells at 24 hours after bleomycin injection
might not be clinically relevant, because IPF is considered a
chronic disease. Third, the optimal media for culturing LSCs war-
rants further investigation. Normally FBS-free media containing
EGF is used for lung epithelial stem cell culture. We compared
LSCs cultured in two conditions: (a) 25 ng/ml EGF and no FBS;
and (b) 20% FBS and no EGF. Themorphologies of LSCs were sim-
ilar in those two conditions, albeit the cells cultured in 20% FBS
media grew faster (supplemental online Fig. 9). These yet-to-be
elucidated questions will be the effort of our future directions
in this line of research. As an autologous product, we anticipate
an IPF patientwill come to the clinic, and a lung biopsywill be per-
formed to generate the tissues required for LSC culture. These au-
tologous cells will then be reintroduced into the same patient by
intravenous injection. To this end, we have confirmed that LSCs
can be derived frommouse (supplemental online Fig. 10) and hu-
man (supplemental online Fig. 11) lungs with PF. Future studies
are also warranted to elucidate the regenerative potential of
PF lung-derived LSCs, the origin of LSCs, and the mechanisms un-
derlying their therapeutic benefits and to translate these findings
into a clinically relevant large animal model of lung disease.
CONCLUSION
We identified lung spheroids from healthy human lungs as a great
source of lung progenitor cells that can be used for therapeutic
Figure 6. Therapeutic superiority of LSCs over AD-MSCs. (A): Schematic showing the design of the rat studies. (B): Hematoxylin and eosin
staining of rat lung sections 14 days after treatment with saline, AD-MSCs, or LSCs. (C): Quantitation of fibrous thickening by Ashcroft score
from H&E staining images (n = 5 animals per group). (D): Quantitation of tissue infiltrates from H&E staining images (n = 5 animals per group).
Data are presented as mean6 SD. Scale bars = 100 mm. p, p, .05. Abbreviations: AD-MSCs, adipose-derived mesenchymal stem cells; Bleo,
bleomycin; LSCs, lung spheroid cells; WKY, Wistar-Kyoto.
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lung regeneration. Lung spheroids represent a simple and highly
reproducible method to generate therapeutic lung cells without
antigenic sorting.
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